The stock gained nearly 6 percent Wednesday but dropped more than 20 percent in afternoon trading the following day, ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

These forward-looking statements are not based on historical fact and include statements regarding: Athira's drug candidates ...

Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while ...

"We are pleased with our operational and clinical execution this quarter and look forward to sharing additional clinical data ...

NextCure expects financial resources to fund operating expenses and capital expenditures into the second half of 2026. Research and development expenses were $8.8 million for the three months ended ...

Rent-control backers termed that the “revenge initiative,” as it limited the ability of the healthcare group to spend ...

When you need to work with the health care provider you have, here’s how to advocate for yourself, even while wearing a ...

PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

Third quarter 2024 research and development expenses were $22.7 million compared to $19.3 million for the same period in 2023. The increase was driven by increased expenses incurred in connection with ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

Operator instructions] I would now like to turn the conference over to Aron Feingold, vice president of investor relations ...